Overview

Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
King's College Hospital NHS Trust
Treatments:
Daclizumab
Immunoglobulin G